Bone and Mineral Metabolism Disorders News

Diabetes mellitus may modify the link between chronic kidney disease-mineral and bone disorder biomarkers and aortic stiffness in adults on peritoneal dialysis, according to recently published data.

The FDA has added a boxed warning for denosumab to advise patients with advanced chronic kidney disease of an increased risk for severe hypocalcemia, according to an FDA drug safety communication.

Long-term use of the potassium binder patiromer may improve clinical outcomes among patients with chronic kidney disease and hyperkalemia, according to a study.

PHILADELPHIA — Gout prevalence in U.S. adults with chronic kidney disease is expected to markedly increase during the next 12 years, suggests data presented at ASN Kidney Week.

Upacicalcet, an injectable calcimimetic, may be an effective and safe therapy for adults with secondary hyperparathyroidism on hemodialysis, according to a recently published study.

While SGLT2 inhibitors are often associated with bone and mineral metabolism irregularities, it remains unclear if these are linked to higher fracture risk in patients with chronic kidney disease, according to recently published research.

Plant-based protein may preserve kidney function and help manage chronic kidney disease in certain patients, but current research remains limited to inform clinical direction, according to published data.

AUSTIN, Texas — In this video at the National Kidney Foundation Spring Clinical Meetings, Glenn W. Brietzke, MS, RD, LD, CNSC, discusses his award-winning poster presentation at the National Kidney Foundation Spring Clinical Meetings.

AUSTIN, Texas —Results from a poster presentation here showed that patients with uncontrolled gout treated with the combined therapy of pegloticase and methotrexate saw a reduction in gout symptoms as well as a stable eGFR.